Dorgenmeltucel-L

Summary

Dorgenmeltucel-L (CHEMBL3301573) is a phase-3 clinical-stage cell; indicated across 2 conditions including acute myeloid leukemia and severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Cell
• Indications: 2 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3301573
Name	Dorgenmeltucel-L
Type	Cell
Max phase	3

Also known as: Dorgenmeltucel-l, HAM, Hyperacute-melanoma, NLG-12036, DORGENMELTUCEL-L

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
Not specified	6
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02461537	PHASE3	COMPLETED	Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML
NCT00300612	PHASE1/PHASE2	COMPLETED	Vaccine Treatment for Advanced Malignant Melanoma
NCT07081945	Not specified	RECRUITING	hAM for Inferior RRD
NCT00994526	Not specified	COMPLETED	Processed Meat and Colon Carcinogenesis
NCT02400411	Not specified	UNKNOWN	The Glycemic and Insulinemic Responses Elicited by Meals Containing Whole Grain Rye Bread or White Wheat Bread
NCT02473302	Not specified	COMPLETED	Preventive Strategies in Colorectal Carcinogenesis Production and Meat Processing
NCT03337243	Not specified	COMPLETED	Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton’s Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis
NCT04967963	Not specified	COMPLETED	Surgical Management of Stage-2 MRONJ With Transplantation of HAM

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).